Polymorphisms in tumor necrosis factor and lymphotoxin a in tuberculosis without and with response to treatment

Inflammation

Volumn 33, Issue 4, 2010, Pages 267-275

  García Elorriaga, Guadalupe ^a   Carrillo Montes, Guadalupe ^a   Mendoza Aguilar, Melby ^a   González Bonilla, César ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Alleles; Genotypes; Pulmonary tuberculosis; SNPs

Indexed keywords

AMIKACIN; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LYMPHOTOXIN; OFLOXACIN; PYRAZINAMIDE; RIBAVIRIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; AGED; ALLELE; ANTIBIOTIC RESISTANCE; GENETIC PREDISPOSITION; GENETICS; MEXICO; MIDDLE AGED; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHOTOXIN-ALPHA; MALE; MEXICO; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77956185422     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10753-010-9181-8     Document Type: Article

References (39)

1. Mira, J.P., A. Cariou, F. Grall, C. Delclaux, M.R. Losser, F. Heshmati, et al. 1999. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. Journal of the American Medical Association 282(6): 561-568.
2. Read, R.C., N.J. Camp, F.S. di Giovine, R. Borrow, E.B. Kaczmarski, A.G. Chaudhary, et al. 2000. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. Journal of Infectious Diseases 182(5): 1557-1560.
3. Bidwell, J., L. Keen, G. Gallagher, R. Kimberly, T. Huizinga, M.F. McDermott, et al. 1999. Cytokine gene polymorphism in human disease: On-line databases. Genes and Immunity 1(1): 3-19.
4. Nedwin, G.E., S.L. Naylor, A.Y. Sakaguchi, D. Smith, J. Jarrett- Nedwin, D. Pennica, et al. 1985. Human lymphotoxin and tumor necrosis factor genes: Structure, homology and chromosomal localization. Nucleic Acids Research 13(17): 6361-6373.
5. Milner, C.N., R.C. Duncan, and J. Trowsdale. 2000. Molecular genetics of the major histocompatibility complex. In HLA in health and disease, ed. Robert Lechler and Antony Warrens, 35-50. San Diego: Academic.
6. Meenagh, A., F. Williams, O.A. Ross, C. Patterson, C. Gorodezky, M. Hammond, et al. 2002. Frequency of cytokine polymorphisms in populations from Western Europe, Africa, Asia, the Middle East and South America. Human Immunology 63: 1055-1061.
7. Roberts, A.K., F. Monzon-Bordonaba, P.G. Van Deerlin, J. Holder, G.A. Macones, M.A. Morgan, et al. 1999. Association of polymorphism within the promoter of the tumor necrosis factor alpha gene with increased risk of preterm premature rupture of the fetal membranes. American Journal of Obstetrics and Gynecology 180(5): 1297-1302.
8. Pociot, F., L. Briant, C.V. Jongennel, et al. 1993. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: A possible link to insulin-dependent diabetes mellitus. European Journal of Immunology 23(1): 224-231.
9. Keane, J. 2005. TNF-blocking agents and tuberculosis: New drugs illuminate an old topic. Rheumatology 44(6): 714-720.
10. Miller, E.A., and J.D. Ernst. 2009. Anti-TNF immunotherapy and tuberculosis reactivation: Another mechanism revealed. Journal of Clinical Investigation 119(5): 1079-1082.
11. Delgado, J.C., A. Baena, S. Thim, and A.E. Goldfeld. 2002. Ethnic-specific genetic associations with pulmonary tuberculosis. Journal of Infectious Diseases 186(10): 1463-1468.
12. Goldfeld, A.E., J.C. Delgado, S. Thim, M.V. Bozon, A.M. Uglialoro, D. Turbay, et al. 1998. Association of an HLA-DQ allele with clinical tuberculosis. Journal of the American Medical Association 279(3): 226-228.
13. Zúñiga-Ramos, J., E. Pérez-Lina, V. Quiróz, et al. 2000. Aspectos Inmunogenéticos de la Tuberculosis Pulmonar. Revista del Instituto Nacional de Enfermedades Respiratorias, México 13(4): 240-247.
14. Selvaraj, P., U. Sriram, K.S. Mathan, A.M. Reetha, and P.R. Narayanan. 2001. Tumour necrosis factor alpha (-238 and -308) and beta gene polymorphisms in pulmonary tuberculosis: Haplotype analysis with HLA-A, B and DR genes. Tuberculosis (Edinburgh) 81(5-6): 335-341.
15. Pacheco, A.G., C.C. Cardoso, andM.O.Moraes. 2008. INFG +874T/ A, IL-10-1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: A meta-anaysis study. Human Genetics 123(5): 477-484.
16. Bayley, J.P., T.H. Ottenhoff, and C.L. Verweij. 2004. Is there a future for TNF promoter polymorphisms? Genes and Immunity 5 (5): 315-329.
17. Abraham, L.J., and K.M. Kroeger. 1999. Impact of the -308 TNF promoter plymorphism on the transcriptional regulation of the gene: Relevance to disease. Journal of Leukocyte Biology 66(4): 562-566.
18. Estados Unidos Mexicanos. 1993. Norma Oficial Mexicana para la Dispocisión de Sangre Humana y sus componentes con fines terapéuticos. NOM-003-SSA2-1993. doi:10.1001/jama.297.6.576.
19. Majetschak, M., S. Flohe, U. Obertacke, J. Schroder, K. Staubach, D. Nast-Kolb, et al. 1999. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Annals of Surgery 230(2): 207-214.
20. Chomczynski, P. 1993. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15(3): 532-537.
21. Stuber, F., M. Petersen, F. Bokelmann, and U. Schade. 1996. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Critical Care Medicine 24 (3): 381-384.
22. Dell, B.R., S. Holleran, and R. Ramakrishnan. 2002. Sample size determination. ILAR Journal 43(4): 207-213.
23. Wilson, A.G., J.A. Symons, T.L. McDowell, H.O. McDevitt, and G.W. Duff. 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proceedings of the National Academy of Sciences of the United States of America 94(7): 3195-3199.
24. McGuire, W., A.V. Hill, C.E. Allsopp, B.M. Greenwood, and D. Kwiatkowski. 1994. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 371 (6497): 508-510.
25. Al Attiyah, R., N. Madi, A.S. El Shamy, H. Wiker, P. Andersen, and A. Mustafa. 2006. Cytokine profiles in tuberculosis patients and healthy subjects in response to complex and single antigens of Mycobacterium tuberculosis. FEMS Immunology and Medical Microbiology 47(21): 254-26.
26. Deveci, F., H.H. Akbulut, T. Turgut, and M.H. Muz. 2005. Changes in serum cytokine levels in active tuberculosis with treatment. Mediators of Inflammation 51: 256-262.
27. Correa, P.A., L.M. Gómez, and J.M. Anaya. 2004. Polymorphism of TNF-alpha in autoimmunity and tuberculosis. Biomedica 24 (Suppl 1): 43-51.
28. Hoffmann, S.C., E.M. Stanley, E.D. Cox, B.S. DiMercurio, D.E. Koziol, D.M. Harlan, et al. 2002. Ethnicity greatly influences cytokine gene polymorphism distribution. American Journal of Transplantation 2(6): 560-567.
29. Sánchez-Castillo, C.P., O. Velásquez-Monroy, A. Lara-Esqueda, A. Berber, J. Sepúlveda, R. Tapia-Conyer, et al. 2005. Diabetes and hypertension increases in a society with abdominal obesity: Results of the Mexican National Health Survey 2000. Public Health Nutrition 8(1): 53-60.
30. Singla, R., N. Khan, N. Al-Sharif, et al. 2006. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. International Journal of Tuberculosis and Lung Disease 10(1): 74-79.
31. Veenstra, H., R. Baumann, N.M. Carroll, et al. 2006. Changes in leucocyte and lymphocyte subsets during tuberculosis treatmen; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clinical and Experimental Immunology 145(2): 252-260.
32. Kankova, K., I. Marova, E.H. Jansen, A. Vasku, M. Jurajda, and J. Vacha. 2002. Polymorphism Ncol in tumor necrosis factor B is associated with fasting glycemia and lipid parameters in healthy non-obese Caucasian subjects. Diabetes & Metabolism 28(3): 231-237.
33. Laniado-Laborín, R., and N. Cabrales-Vargas. 2000. Tratamiento acortado estrictamente supervisado: Estrategia necesaria pero no suficiente para controlar la tuberculosis en Baja California, México. Revista del Instituto Nacional de Enfermedades Respiratorias, México 13(1): 23-27.
34. Frothingham, R. 2000. Mycobacteria: Treatment approaches and mechanisms of resistance. Journal ofMedicine Liban 48(4): 248-254.
35. Aguillon, J.C., A. Cruzat, O. Aravena, L. Salazar, C. Llanos, and M. Cuchacovich. 2006. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 211(1-2): 75-84.
36. Szatmary, Z. 1999. Tumor necrosis factor-alpha: Molecular-biological aspects minireview. Neoplasma 46(5): 257-266.
37. Debets, J.M., R. Kampmeijer, M.P. van der Linden, W.A. Buurman, and C.J. van der Linden. 1989. Plasma tumor necrosis factor and mortality in critically ill septic patients. Critical Care Medicine 17(6): 489-494.
38. Gerloni, V., I. Pontikaki, M. Gattinara, et al. 2007. Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience. Reumatismo 59(3): 244-261.
39. Theis, V.S., and J.M. Rhodes. 2008. Review article: Minimizing tuberculosis during anti-TNF-alpha treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 27(1): 19-30.